Shots:

• The approval is based on Japanese P-III study results assessing Humira (adalimumab) in patients with moderate-to-severe HS- evaluating its efficacy and safety
• The study resulted in meeting its 1EPs as HiSCR @12 wks. in 13/15 patients- ADRs in 6/15
• Humira (adalimumab) is an anti-TNF-α mAb approved in Japan for rheumatoid arthritis (RA)- plaque psoriasis- arthritic psoriasis- pustular psoriasis- ankylosing spondylitis

Ref: Eisai Co | Image: AbbVie